The Securities and Exchange Commission (SEC) is proposing to make significant changes to the eligibility of issuers to utilize Securities ...
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) ("Biodexa” or the "Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with ...
Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results